GlassScriptPhysician profile
Paul Nava
NPI 1457863227
$2,581.32
in general payments reported to CMS, 2019-2025
25 companies · $108 in 2025
The $108 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $563 · 2022: $1,159 · 2023: $485 · 2024: $267 · 2025: $108.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $860.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $859.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $493.05 | 2021-2024 | |
| Abiomed | $283.33 | 2022-2025 | Impella |
| Atricure, INC. | $274.97 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $208.98 | 2022-2025 | Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $196.53 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $151.13 | 2021-2024 | Farxiga |
| Boston Scientific Corporation | $149.10 | 2022-2024 | Watchman Flx, Watchman Access System |
| Amgen INC. | $103.16 | 2021-2025 | Repatha |
| Nestle Healthcare Nutrition INC. | $94.11 | 2021 | |
| Pfizer INC. | $89.99 | 2022-2024 | |
| Janssen Pharmaceuticals, INC | $63.60 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $63.49 | 2021-2023 | Lifevest |
| Esperion Therapeutics, INC. | $61.18 | 2021-2022 | |
| Abbvie INC. | $59.05 | 2021 | |
| Redhill Biopharma INC. | $45.36 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $45.33 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $39.95 | 2021 | |
| Chiesi USA, INC. | $35.95 | 2022-2025 | Kengreal |
| Abbott Laboratories | $22.70 | 2022 | |
| Medtronic, INC. | $22.54 | 2022 | |
| Kestra Medical Technology Services, INC. | $18.07 | 2022 | |
| Regeneron Pharmaceuticals, INC. | $17.33 | 2024 | Evkeeza |
| Cvrx, INC. | $16.51 | 2024 | Barostim Neo System |
| Kiniksa Pharmaceuticals, LTD. | $13.78 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.13 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Nava listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.